单纯降糖治疗对初诊T_2DM患者血脂的影响

• 作 者: 刘晓丽 韩峰 张卫民 荣海钦
• 机 构: 山东省内分泌与代谢病研究所,山东省章丘市人民医院,山东省章丘市妇幼保健院,
• 出 处: 实用糖尿病杂志
• 发表日期: 2009年04期
• 关键词: 降糖治疗 T_2DM 血脂异常 双胍 二甲 格列美脲 血脂 血糖 继发性糖尿病 糖耐量试验

将入选的100例(男52例;女48例)伴血脂异常的初诊T2DM患者按体重指数分为二甲双胍组和格列美脲组,持续治疗12周。结果无论是二甲双胍组还是格列美脲组经降糖治疗后FPG、HbA1c、TC、TG、LDL、Apo-b均有下降(P<0.01),HDL、Apo-a有所上升(P<0.01,P<0.05);组间比较,二甲双胍组TC下降显著(P<0.05);TG、LDL的下降与HbA1c呈正相关(P<0.01)。结论伴有血脂异常的初诊T2DM在治疗早期可通过单纯控制血糖改善血脂,二甲双胍与格列美脲可作为一线选择药物。

The selected 100 patients (52 males and 48 females) with newly diagnosed T2DM with dyslipidemia were divided into metformin group and glimepiride group according to their body mass index, and were treated for 12 weeks. Results The levels of FPG, HbA1c, TC, TG, LDL and Apo-b in both metformin and glimepiride groups decreased (P <0.01) and HDL and Apo-a increased , P <0.05). TC in metformin group decreased significantly (P <0.05). The decrease of TG and LDL was positively correlated with HbA1c (P <0.01). Conclusions The newly diagnosed T2DM with dyslipidemia can be used to improve the blood lipid level by simply controlling blood glucose in the early stage of treatment. Metformin and glimepiride can be used as first-line choice drugs.